隽泰控股2023中期报告

(Stock Code: 630)(Incorporated in Bermuda with limited liability) 2023INTERIM REPORT中 期 報 告 Contents Management Discussion and Analysis2Corporate Governance and Other Information13Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income21Interim Condensed Consolidated Statement of Financial Position22Interim Condensed Consolidated Statement of Changes in Equity23Interim Condensed Consolidated Statement of Cash Flows24Notes to the Interim Condensed Consolidated Financial Statements25 Management Discussion and Analysis RESULTS, BUSINESS REVIEW AND PROSPECTS Results (i)(ii)(iii)(iv)(v) For the six months ended 30 June 2023, AMCO United Holding Limited(the“Company”)and its subsidiaries(collectively referred to as the“Group”) are principally engaged in (i) manufacture and sale of medicaldevices products (“Medical Products Business”); (ii) manufacture and saleof plastic moulding products (“Plastic Products Business”); (iii) provisionof construction services in building construction, building maintenanceandimprovement works,project management,renovation anddecorationworks(“Building Contract Works Business”);(iv)provisionof money lending (“Money Lending Business”); and (v) investment insecurities (“Securities Investment”). 23,300,00025,000,0001,700,0006.8% Duringthe period under review,revenue of the Group amounted toHK$23.3million,representing a decrease of HK$1.7 million or 6.8%fromHK$25.0 million for the corresponding period last year.Suchdecrease was mainly attributable to the decrease in revenue from theMedicalProducts Business,Plastic Moulding Business and BuildingContract Works Business. Gross profit of the Group was HK$4.9 million, representing a decreaseofHK$2.2 million or 31.0%as compared to HK$7.1 million for thecorresponding period last year. Gross profit margin slightly decreased by7.2 percentage points to 21.1% (30 June 2022: 28.3%). 4,900,0007,100,0002,200,00031.0%7.221.1%28.3% 20,300,00010,600,000 Other losses, net of other income and other gains, during the periodunderreview recorded loss of HK$20.3 million as compared to lossof HK$10.6 million in the corresponding period of 2022. The amountincluded realised and unrealised fair value gain/(loss) of held-for-tradinginvestments arising from Securities Investment and the change of fairvalue on financial liabilities at fair value through profit or loss in thecurrent period. Management Discussion and Analysis 5 0 0 , 0 0 02 , 7 0 0 , 0 0 03,200,00011,600,00010,100,00021,700,00053.5%(i)(ii)9,200,000 The distribution costs decreased by HK$0.5 million to HK$2.7 millionduringthe period under review(30 June 2022:HK$3.2 million),alongside with the decrease in revenue of MedicalProducts Businessand Plastic Products Business. The administrative expenses decreased byHK$11.6 million to HK$10.1 million (30 June 2022: HK$21.7 million),representing a decrease of 53.5% over the corresponding period lastyear, primarily as a result of the combined effect of (i) the decrease ingeneraladministrative costs under stringent cost control during thecurrent period; and (ii) the recognition of share-based payment expenseof HK$9.2 million during the period ended 30 June 2022. 1,400,0001,800,000 Financecosts amounted to HK$1.4 million(30 June 2022:HK$1.8million) for the period under review, which represented interest on bondpayables and lease liabilities. As a result, the overall loss attributable to owners of the Company wasHK$29.7 million, which decreased by HK$0.5 million as compared toHK$30.2 million loss for the corresponding period of 2022. Excludingthe other income and other gains or losses and the share-based paymentexpenses, the loss for the six months ended 30 June 2023 was HK$9.4million,which decreased by HK1.0 million as compared to HK$10.4million loss for the corresponding period of 2022. 29,700,00030,200,000500,0009,400,00010,400,0001,000,000 Business Review Medical Products Business 600,0003.5%1 6 , 4 0 0 , 0 0 017,000,00070.4% For the six months ended 30 June 2023, the revenue from the MedicalProductsBusiness decreased by HK$0.6 million or 3.5%to HK$16.4million, as compared to revenue of HK$17.0 million recorded in the sameperiod last year, which accounted for 70.4% of the Group’s total revenuefor the period under review. In the first half of 2023, the sales demandof Medical Products Business decrease due to the keen competition inthe industry. Management Discussion and Analysis Segment profit of the Medical Products Business amounted to HK$1.4million for the six months ended 30 June 2023, as compared to segmentprofit of HK$1.0 million in the corresponding period last year. To copewith the challenge of fluctuating sales order, the Group is persisting todeploy business strategies of streamlining and outsourcing of businessprocesses,implementing strict cost control and ensuring effectiveutilisation of resources with an aim to maintain its long-term sustainablecompetitiveadvantages in the business segment.In